How are pharmaceutical companies working with each other to promote the advancement of drug development? This question is on the mind of many as we hear key phrases like ‘the blockbuster era is over’ in the media. Last week, I had a chance to chat with a collective group of leaders from Merck, Eli Lilly & Co and Janssen Pharmaceuticals to discuss a new platform for open collaboration amongst the so-called competitors. Fueled by a technology connecting drug researchers across the globe, the group has started an Open Investigator Databank initiative – a cross-pharmaceutical Investigator Databank with the mission to make it easier for drug makers to locate up-to-date information on clinical trial investigators and sites, and avoid duplicating efforts along the way.
Want to learn more? You’ll hear at the Partnerships in Clinical Trials conference FIRST! Join us from 7:30am – 8:45 on Monday, April 22nd when we will be hosting an exclusive open information session with industry insights into the details of this collaboration and how your company can get involved. Plus, get all of your questions answered directly from the source:
- • Elise Felicione, Director, Clinical Trial Innovation at Janssen Pharmaceuticals
- • Laura Galuchie, Director, Global Trial Management and Therapeutic Area Lead for Respiratory & Immunology at Merck
- • Michael Luker, Sr. Advisor, Clinical Research Innovation at Eli Lilly